Scemblix improves MMR rates for Ph+ CML-CP in phase III trial

Calquence combination significantly improved PFS in CLL in phase III trial

Positive high-level results from an interim analysis of the AMPLIFY phase III trial showed a fixed duration of Calquence (acalabrutinib) in combination with venetoclax, with or without obinutuzumab, demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared to standard-of-care chemoimmunotherapy in previously untreated adult patients with chronic lymphocytic leukemia.

August 02, 2024

Vol.50 No.31

Clinical Roundup

Modifying, deleting, or degrading protein ZFP574 reduces division of malignant B cells in lab

Targeting a protein called ZFP574 suppressed leukemia in a mouse model of the disease, UT Southwestern Medical Center researchers showed in a new study. Their findings, published in PNAS, could lead to new treatments for leukemias and lymphomas in cancer patients.

August 02, 2024

Vol.50 No.31

Drugs & Targets

FDA grants Priority Review to Scemblix for newly-diagnosed Ph+ CML-CP

FDA has granted Priority Review status to Scemblix (asciminib) for treatment of newly-diagnosed adult patients with Philadelphia chromosome-positive CML in chronic phase.

August 02, 2024

Vol.50 No.31

In Brief

Matt Kalaycio named chair of board of directors at NCCN

Matt Kalaycio was named chair of the board of directors at the National Comprehensive Cancer Network. Christopher H. Lieu was elected as vice chair, succeeding Kalaycio in the position he has held since 2022.

April 12, 2024

Vol.50 No.15

In Brief

Christopher Hourigan named professor and director of Cancer Research Center at Virginia Tech

Christopher Hourigan, a senior investigator and chief of the Laboratory of Myeloid Malignancies at the National Institutes of Health, will join Virginia Tech as a professor with the institute and director of its Fralin Biomedical Research Institute Cancer Research Center in Washington, D.C.

April 05, 2024

Vol.50 No.14

Clinical Roundup

Novel treatment for T-cell leukemias and lymphomas demonstrates promise in preclinical study

A novel treatment for leukemias and lymphomas that arise from immune system T cells, developed by investigators at the Johns Hopkins Kimmel Cancer Center and its Ludwig Center and Lustgarten Laboratory, was found to be effective at killing these cancers in mice bearing human T-cell tumors.

April 05, 2024

Vol.50 No.14

Scemblix improves MMR rates for Ph+ CML-CP in phase III trial

YOU MAY BE INTERESTED IN

Calquence combination significantly improved PFS in CLL in phase III trial

Modifying, deleting, or degrading protein ZFP574 reduces division of malignant B cells in lab

FDA grants Priority Review to Scemblix for newly-diagnosed Ph+ CML-CP

Matt Kalaycio named chair of board of directors at NCCN

Christopher Hourigan named professor and director of Cancer Research Center at Virginia Tech

Novel treatment for T-cell leukemias and lymphomas demonstrates promise in preclinical study

Renew today!

Subscriber content

Can you spare 10 minutes to complete a survey?

Login